KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor

Abstract excerpt

Abstract Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high-risk tumors. We hypothesized that GIST contains cells with primary IM resistance that may represent a reservoir for disease persistence. Here, we report a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal Tumor Research and Treatment
• Share to Phagocytosis and Immune Regulation
• Share to Sarcoma Diagnosis and Treatment